Abbisko Cayman (HKG:2256) subsidiary has dosed the first patient in the U.S. in the expansion phase of a global Phase 1 clinical study of its FGFR4 inhibitor irpagratinib, according to a Wednesday Hong Kong bourse filing.
The multicenter trial is evaluating irpagratinib in patients with advanced hepatocellular carcinoma with FGF19 overexpression, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.